European company

Tafalgie Therapeutics is going to participate in the ‘IPOready’ 2024 program, a pre-IPO program organized by Euronext for the 9th consecutive year Tafalgie Therapeutics, a biopharmaceutical research company specialised in the research and innovation of treatments capable of alleviating and preventing the onset of acute and chronic pain (inflammatory, post-operative, neuropathic) without side effects, is […]

Lire la suite
Visit our contact page